Christopher Trotta
Senior Vice President of Discovery Biology PTC Therapeutics
Chris earned a PhD in biochemistry and molecular biology from the California Institute of Technology where he studied tRNA splicing in the lab of John Abelson. He then pursued a Damon Runyon postdoctoral fellowship focusing on ribosome transport from the nucleus, in the lab of James Dahlberg at the University of Wisconsin-Madison. Following his postdoc, Chris joined PTC Therapeutics as a Scientist. As head of PTC’s discovery efforts, Chris spearheaded the discovery of small molecule modulators of gene expression. Chris has contributed to numerous programs at PTC, notably the discovery and development of votoplam (PTC518), an oral therapy in clinical trials for the treatment of Huntington’s Disease. As Senior Vice President of Discovery Biology, Chris currently leads the biology team to advance the PTSeek splicing platform at PTC.
Seminars
- Expanding splice modulation into new RNA sequence contexts to identify novel therapeutic targets
- Decoding how RNA–small molecule interactions drive binding, splice site recognition and modulation mechanisms
